Genetic, Immune Biomarkers Can Help Predict Response to QBECO SSI Treatment, UC Trial Suggests

Genetic, Immune Biomarkers Can Help Predict Response to QBECO SSI Treatment, UC Trial Suggests
Detection of specific genetic alterations and immunological biomarkers can help predict the response to QBECO SSI immunotherapy in patients with inflammatory bowel disease (IBD). This finding resulted from the analysis of Phase 2 trial data in ulcerative colitis. QBECO SSI therapy was developed by Qu Biologics based on the company’s Site Specific Immunomodulators (SSIs) platform.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *